Serum proteome changes in acromegalic patients following transsphenoidal surgery: Novel biomarkers of disease activity

European Journal of Endocrinology

Volumn 164, Issue 2, 2011, Pages 157-167

  Cruz Topete, Diana ^a   Christensen, Britt ^b   Sackmann Sala, Lucila ^a,c   Okada, Shigeru ^a,c   Jorgensen, Jens Otto L ^b   Kopchick, John J ^a,c  

^a OHIO UNIVERSITY   (United States)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c OHIO UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; BIOLOGICAL MARKER; COMPLEMENT COMPONENT C4B; GROWTH HORMONE; HAPTOGLOBIN; HAPTOGLOBIN ALPHA 2; HEMOGLOBIN BETA CHAIN; PREALBUMIN; PROTEOME; SOMATOMEDIN C; UNCLASSIFIED DRUG; ISOPROTEIN;

ACROMEGALY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TANDEM MASS SPECTROMETRY; TRANSSPHENOIDAL SURGERY; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING; CLINICAL EFFECTIVENESS; FUNCTIONAL PROTEOMICS; GROWTH HORMONE BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ACROMEGALY; ADENOMA; ADULT; AGED; BIOLOGICAL MARKERS; BLOTTING, WESTERN; DATABASES, FACTUAL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HAPTOGLOBINS; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PREALBUMIN; PROTEOME; PROTEOMICS; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME;

EID: 78751548110     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0754     Document Type: Article

References (66)

1. Kopchick JJ, Parkinson C, Stevens EC & Trainer PJ. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocrine Reviews 2002 23 623-646. (doi:10.1210/er.2001-0022) (Pubitemid 35191626)
2. Moller N & Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocrine Reviews 2009 30 152-177. (doi:10.1210/er.2008-0027)
3. Berryman DE, List EO, Palmer AJ, Chung MY, Wright-Piekarski J, Lubbers E, O'Connor P, Okada S & Kopchick JJ. Two-year body composition analyses of long-lived GHR null mice. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 2009 65 31-40. (doi:10.1093/gerona/glp175)
4. List EO, Palmer AJ, Berryman DE, Bower B, Kelder B & Kopchick JJ. Growth hormone improves body composition, fasting blood glucose, glucose tolerance and liver triacylglycerol in a mouse model of diet-induced obesity and type 2 diabetes. Diabetologia 2009 52 1647-1655. (doi:10.1007/s00125-009-1402- z)
5. Dostalova S, Sonka K, Smahel Z,Weiss V & Marek J. Cephalometric assessment of cranial abnormalities in patients with acromegaly. Journal of Cranio-Maxillo-Facial Surgery 2003 31 80-87. (doi:10.1016/S1010-5182(02)00182-8)
6. Ayuk J & Sheppard MC. Does acromegaly enhance mortality? Reviews in Endocrine & Metabolic Disorders 2008 9 33-39. (doi:10.1007/s11154-007-9067- 8)
7. Loeper S & Ezzat S. Acromegaly: re-thinking the cancer risk. Reviews in Endocrine & Metabolic Disorders 2008 9 41-58. (doi:10.1007/s11154-007- 9063-z)
8. Holdaway IM, Bolland MJ & Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. European Journal of Endocrinology 2008 159 89-95. (doi:10.1530/EJE-08-0267)
9. Ebner FH, Kuerschner V, Dietz K, Bueltmann E, Naegele T & Honegger J. Reduced intercarotid artery distance in acromegaly: pathophysiologic considerations and implications for transsphenoidal surgery. Surgical Neurology 2009 72 456-460 (discussion 460). (doi:10.1016/j.surneu.2009.07.006)
10. Gondim JA, Ferraz T, Mota I, Studart D, Almeida JP, Gomes E & Schops M. Outcome of surgical intrasellar growth hormone tumor performed by a pituitary specialist surgeon in a developing country. Surgical Neurology 2009 72 15-19 (discussion 19). (doi:10.1016/j.surneu.2008.02.012)
11. Melmed S. Acromegaly pathogenesis and treatment. Journal of Clinical Investigation 2009 119 3189-3202. (doi:10.1172/JCI39375)
12. Petrossians P, Borges-Martins L, Espinoza C, Daly A, Betea D, Valdes-Socin H, Stevenaert A, Chanson P & Beckers A. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. European Journal of Endocrinology 2005 152 61-66. (doi:10.1530/eje.1.01824)
13. Shimon I, Cohen ZR, RamZ & Hadani M. Transsphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients. Neurosurgery 2001 48 1239-1243 (discussion 1244-1245). (doi:10.1097/00006123-200106000-00008)
14. Damjanovic SS, Neskovic AN, Petakov MS, Popovic V, Macut D, Vukojevic P & Joksimovic MM. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure? Clinical Endocrinology 2005 62 410-417. (doi:10.1111/j.1365-2265.2005.02233.x)
15. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K & Melmed S. Criteria for cure of acromegaly: a consensus statement. Journal of Clinical Endocrinology and Metabolism 2000 85 526-529. (doi:10.1210/jc.85.2.526)
16. Carmichael JD, Bonert VS, Mirocha JM & Melmed S. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 2009 94 523-527. (doi:10.1210/jc.2008-1371)
17. Jorgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LO, Hagen C & Orskov H. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. Journal of Clinical Endocrinology and Metabolism 2005 90 5627-5631. (doi:10.1210/jc.2005-0531)
18. List EO, Berryman DE, Palmer AJ, Qiu L, Sankaran S, Kohn DT, Kelder B, Okada S & Kopchick JJ. Analysis of mouse skin reveals proteins that are altered in a diet-induced diabetic state: a new method for detection of type 2 diabetes. Proteomics 2007 7 1140-1149. (doi:10.1002/pmic.200600641) (Pubitemid 46649163)
19. Sackmann-Sala L, Ding J, Frohman LA & Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone and IGF Research 2009 19 471-477. (doi:10.1016/j.ghir.2009.03.001)
20. Qiu L, List EO & Kopchick JJ. Differentially expressed proteins in the pancreas of diet-induced diabetic mice. Molecular and Cellular Proteomics 2005 4 1311-1318. (doi:10.1074/mcp.M500016-MCP200)
21. Ding J, List EO, Okada S & Kopchick JJ. Perspective: proteomic approach to detect biomarkers of human growth hormone. Growth Hormone and IGF Research 2009 19 399-407. (doi:10.1016/j.ghir.2009.04.018)
22. Salmi J, Moulder R, Filen JJ, Nevalainen OS, Nyman TA, Lahesmaa R & Aittokallio T. Quality classification of tandem mass spectrometry data. Bioinformatics 2006 22 400-406. (doi:10.1093/bioinformatics/bti829)
23. Sheskin D. Handbook of Parametric and Nonparametric Statistical Procedures Boca Raton, FL: CRC Press, 1997.
24. Freda PU, Landman RE, Sundeen RE & Post KD. Gender and age in the biochemical assessment of cure of acromegaly. Pituitary 2001 4 163-171. (doi:10.1023/A:1015314906972)
25. Freda PU. How effective are current therapies for acromegaly? Growth Hormone & IGF Research 2003 13 (Supplement A) S144-S151. (doi:10.1016/S1096-6374(03)00072-8)
26. Freda PU, Nuruzzaman AT, Reyes CM, Sundeen RE & Post KD. Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. Journal of Clinical Endocrinology and Metabolism 2004 89 495-500. (doi:10.1210/jc.2003-031316)
27. Parkinson C, Renehan AG, Ryder WD, O'Dwyer ST, Shalet SM & Trainer PJ. Gender and age influence the relationship between serum GH and IGF-I in patients with acromegaly. Clinical Endocrinology 2002 57 59-64. (doi:10.1046/j.1365-2265.2002.01560.x) (Pubitemid 34785884)
28. Peacey SR & Shalet SM. Insulin-like growth factor 1 measurement in diagnosis and management of acromegaly. Annals of Clinical Biochemistry 2001 38 297-303. (doi:10.1258/0004563011900678)
29. Biermasz NR, van Dulken H & Roelfsema F. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. Journal of Clinical Endocrinology and Metabolism 2000 85 4596-4602. (doi:10.1210/jc.85.12.4596)
30. Kreutzer J, Vance ML, Lopes MB & Laws ER Jr. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. Journal of Clinical Endocrinology and Metabolism 2001 86 4072-4077. (doi:10.1210/jc.86.9.4072)
31. Pokrajac A, Wark G, Ellis AR, Wear J, Wieringa GE & Trainer PJ. Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clinical Endocrinology 2007 67 65-70. (doi:10.1111/j.1365-2265.2007.02836.x)
32. Arafat AM, Mohlig M, Weickert MO, Perschel FH, Purschwitz J, Spranger J, Strasburger CJ, Schofl C & Pfeiffer AF. Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index. Journal of Clinical Endocrinology and Metabolism 2008 93 1254-1262. (doi:10.1210/jc.2007-2084)
33. Webb SM. Quality of life in acromegaly. Neuroendocrinology 2006 83 224-229. (doi:10.1159/000095532)
34. Hellgren G, Andersson B, Nierop AF, Dahlgren J, Hochberg Z & Albertsson-Wikland K. A proteomic approach identified growth hormone-dependent nutrition markers in children with idiopathic short stature. Proteome Science 2008 6 35. (doi:10.1186/1477-5956-6-35)
35. Power DM, Elias NP, Richardson SJ, Mendes J, Soares CM & Santos CR. Evolution of the thyroid hormone-binding protein, transthyretin. General and Comparative Endocrinology 2000 119 241-255. (doi:10.1006/gcen.2000.7520)
36. Fung ET, Yip TT, Lomas L,Wang Z, Yip C, Meng XY, Lin S, Zhang F, Zhang Z, Chan DW&Weinberger SR. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. International Journal of Cancer 2005 115 783-789. (doi:10.1002/ijc.20928) (Pubitemid 40776702)
37. Liu L, Wang J, Liu B, Dai S, Wang X, Chen J, Huang L, Xiao X & He D. Serum levels of variants of transthyretin down-regulation in cholangiocarcinoma. Journal of Cellular Biochemistry 2008 104 745-755. (doi:10.1002/jcb.21661)
38. Hoogland C, Mostaguir K, Sanchez JC, Hochstrasser DF & Appel RD. SWISS-2DPAGE, ten years later. Proteomics 2004 4 2352-2356. (doi:10.1002/pmic. 200300830)
39. Okada S, List EO, Sankaran S & Kopchick JJ. Plasma protein biomarkers correlated with the development of diet-induced type 2 diabetes in mice. Clinical Proteomics 2010 6 6-17. (doi:10.1007/s12014-009-9040-5)
40. Ding J & Kopchick JJ. Plasma biomarkers of mouse aging. Age, 2010. (doi:10.1007/s11357-010-9179-z)
41. Henry JB. Clinical Diagnosis and Management by Laboratory Methods Philadelphia: W.B. Saunders, 2001.
42. Koch W, Latz W, Eichinger M, Roguin A, Levy AP, Schomig A & Kastrati A. Genotyping of the common haptoglobin Hp 1/2 polymorphism based on PCR. Clinical Chemistry 2002 48 1377-1382. (Pubitemid 34925770)
43. Cheng TM, Pan JP, Lai ST, Kao LP, Lin HH & Mao SJ. Immunochemical property of human haptoglobin phenotypes: determination of plasma haptoglobin using type-matched standards. Clinical Biochemistry 2007 40 1045-1056. (doi:10.1016/j.clinbiochem.2007.04.018)
44. Melamed-Frank M, Lache O, Enav BI, Szafranek T, Levy NS, Ricklis RM & Levy AP. Structure-function analysis of the antioxidant properties of haptoglobin. Blood 2001 98 3693-3698. (doi:10.1182/blood.V98.13.3693)
45. Chen CB, Su YC, Huang TT, Ho HC, Chang YT, Tung YT & LeeWC. Differentially expressed serum haptoglobin alpha chain isoforms with potential application for diagnosis of head and neck cancer. Clinica Chimica Acta 2008 398 48-52. (doi:10.1016/j.cca.2008.08.001)
46. Nilsson-Ehle H, Bengtsson BA, Lindstedt G & Mellstrom D. Insulin-like growth factor-1 is a predictor of blood haemoglobin concentration in 70-yr-old subjects. European Journal of Haematology 2005 74 111-116. (doi:10.1111/j.1600- 0609.2004.00374.x)
47. Sohmiya M & Kato Y. Human growth hormone and insulin-like growth factor-I inhibit erythropoietin secretion from the kidneys of adult rats. Journal of Endocrinology 2005 184 199-207. (doi:10.1677/joe.1.05899)
48. Vihervuori E, Virtanen M, Koistinen H, Koistinen R, Seppala M & Siimes MA. Hemoglobin level is linked to growth hormone-dependent proteins in short children. Blood 1996 87 2075-2081. (Pubitemid 26068925)
49. Chung L, Clifford D, Buckley M & Baxter RC. Novel biomarkers of human growth hormone action from serum proteomic profiling using protein chip mass spectrometry. Journal of Clinical Endocrinology and Metabolism 2006 91 671-677. (doi:10.1210/jc.2005-1137)
50. Vollmer RT, Kantoff PW, Dawson NA & Vogelzang NJ. Importance of serum hemoglobin in hormone refractory prostate cancer. Clinical Cancer Research 2002 8 1049-1053.
51. Kozak KR, Amneus MW, Pusey SM, Su F, Luong MN, Luong SA, Reddy ST & Farias-Eisner R. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. PNAS 2003 100 12343-12348. (doi:10.1073/pnas.2033602100) (Pubitemid 37271562)
52. Shoulders CC, Kornblihtt AR, Munro BS & Baralle FE. Gene structure of human apolipoprotein A1. Nucleic Acids Research 1983 11 2827-2837. (doi:10.1093/nar/11.9.2827)
53. Yildiz M, Arslanoglu I, Yildiz N, Nartop F, Isik K & Isguven P. Effects of growth hormone replacement therapy on lipids, lipoproteins and apolipoproteins: is the increased apolipoprotein A-1/B ratio the only benefit? Pediatrics International 2000 42 151-154. (doi:10.1046/j.1442-200x.2000.01193.x)
54. Lanes R, Soros A, Gunczler P, Paoli M, Carrillo E, Villaroel O & Palacios A. Growth hormone deficiency, low levels of adiponectin, and unfavorable plasma lipid and lipoproteins. Journal of Pediatrics 2006 149 324-329. (doi:10.1016/j.jpeds.2006.05.010)
55. Schaefer GB, Greger NG, Fesmire JD, Blackett PR, Wilson DP & Frindik JP. Lipids and apolipoproteins in growth hormone-deficient children during treatment. Metabolism 1994 43 1457-1461. (doi:10.1016/0026-0495(94)90001-9)
56. Blackett PR, Weech PK, McConathy WJ & Fesmire JD. Growth hormone in the regulation of hyperlipidemia. Metabolism 1982 31 117-120. (doi:10.1016/0026-0495(82)90121-4)
57. Parkinson C, Drake WM, Wieringa G, Yates AP, Besser GM & Trainer PJ. Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly. Clinical Endocrinology 2002 56 303-311. (doi:10.1046/j.1365-2265.2002.01460.x)
58. Oscarsson J, Wiklund O, Jakobsson KE, Petruson B & Bengtsson BA. Serum lipoproteins in acromegaly before and 6-15 months after transsphenoidal adenomectomy. Clinical Endocrinology 1994 41 603-608. (doi:10.1111/j.1365-2265. 1994.tb01825.x)
59. Chan AC & Atkinson JP. Functional studies on the secreted form of human C4 (C4s), two incompletely processed two-subunit C4 molecules (beta - alpha + gamma and beta + alpha - gamma), and pro-C4. Journal of Immunology 1984 132 1967-1971.
60. Banyai A, Varga L, Barta A, Gopcsa L & Paloczi K. Monitoring the level of complement components during autologous blood stem cell transplantation in patients with malignant lymphomas. Cancer Immunology, Immunotherapy 2004 53 835-839. (doi:10.1007/s00262-004-0519-7)
61. Blanchong CA, Chung EK, Rupert KL, Yang Y, Yang Z, Zhou B, Moulds JM & Yu CY. Genetic, structural and functional diversities of human complement components C4A and C4B and their mouse homologues, Slp and C4. International Immunopharmacology 2001 1 365-392. (doi:10.1016/S1567-5769(01)00019-4) (Pubitemid 32197537)
62. Belt KT, Carroll MC & Porter RR. The structural basis of the multiple forms of human complement component C4. Cell 1984 36 907-914. (doi:10.1016/0092-8674(84)90040-0)
63. Liao W, Rudling M & Angelin B. Growth hormone potentiates the in vivo biological activities of endotoxin in the rat. European Journal of Clinical Investigation 1996 26 254-258. (doi:10.1046/j.1365-2362.1996.140268.x)
64. Liao W, Rudling M & Angelin B. Contrasting effects of growth hormone and insulin-like growth factor I on the biological activities of endotoxin in the rat. Endocrinology 1997 138 289-295. (doi:10.1210/en.138.1.289)
65. Takala J, Ruokonen E, Webster NR, Nielsen MS, Zandstra DF, Vundelinckx G & Hinds CJ. Increased mortality associated with growth hormone treatment in critically ill adults. New England Journal of Medicine 1999 341 785-792. (doi:10.1056/NEJM199909093411102)
66. Hansen TK, Thiel S, Dall R, Rosenfalck AM, Trainer P, Flyvbjerg A, Jorgensen JO & Christiansen JS. GH strongly affects serum concentrations of mannan-binding lectin: evidence for a new IGF-I independent immunomodulatory effect of GH. Journal of Clinical Endocrinology and Metabolism 2001 86 5383-5388. (doi:10.1210/jc.86.11.5383)